Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers.
Boruah N, Hoyos D, Moses R, Hausler R, Desai H, Le AN, Good M, Kelly G, Raghavakaimal A, Tayeb M, Narasimhamurthy M, Doucette A, Gabriel P, Feldman MJ, Park J, de Rodas ML, Schalper KA, Goldfarb SB, Nayak A, Levine AJ, Greenbaum BD, Maxwell KN. Boruah N, et al. Among authors: doucette a. bioRxiv [Preprint]. 2024 Apr 5:2024.04.03.588009. doi: 10.1101/2024.04.03.588009. bioRxiv. 2024. PMID: 38617260 Free PMC article. Preprint.
Brief Report: Impact of Reflex Testing on Tissue-Based Molecular Genotyping in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
Marmarelis ME, Scholes DG, McGrath CM, Priore SF, Roth JJ, Feldman M, Morrissette JJD, Litzky L, Deshpande C, Thompson JC, Doucette A, Gabriel PE, Sun L, Singh AP, Cohen RB, Langer CJ, Carpenter EL, Aggarwal C. Marmarelis ME, et al. Among authors: doucette a. Clin Lung Cancer. 2024 Mar 12:S1525-7304(24)00037-8. doi: 10.1016/j.cllc.2024.03.002. Online ahead of print. Clin Lung Cancer. 2024. PMID: 38582618 No abstract available.
Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.
Iocolano M, Yegya-Raman N, Friedes C, Wang X, Kegelman T, Lee SH, Duan L, Li B, Levin WP, Cengel KA, Konski A, Langer CJ, Cohen RB, Sun L, Aggarwal C, Doucette A, Xiao Y, Kevin Teo BK, O'Reilly S, Zou W, Bradley JD, Simone CB 2nd, Feigenberg SJ. Iocolano M, et al. Among authors: doucette a. Cancer. 2024 Jan 31. doi: 10.1002/cncr.35230. Online ahead of print. Cancer. 2024. PMID: 38294959
Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
Barsouk A, Friedes C, Iocolano M, Doucette A, Cohen RB, Robinson KW, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Levin WP, Cengel KA, Bradley JD, Feigenberg SJ, Sun L, Aggarwal C, Langer CJ, Yegya-Raman N. Barsouk A, et al. Among authors: doucette a. Clin Lung Cancer. 2023 Dec 22:S1525-7304(23)00266-8. doi: 10.1016/j.cllc.2023.12.009. Online ahead of print. Clin Lung Cancer. 2023. PMID: 38195320
The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC.
Friedes C, Iocolano M, Lee SH, Duan L, Li B, Doucette A, Cohen RB, Aggarwal C, Sun LL, Levin WP, Cengel KA, Kao G, Teo BK, Langer CJ, Xiao Y, Bradley J, Feigenberg SJ, Yegya-Raman N. Friedes C, et al. Among authors: doucette a. Radiother Oncol. 2024 Jan;190:110030. doi: 10.1016/j.radonc.2023.110030. Epub 2023 Nov 24. Radiother Oncol. 2024. PMID: 38008414
138 results